Literature DB >> 26558807

Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient.

Teena Bhatla1, Smita Dandekar, Benjamin Y Lu, Jinhua Wang, Eugenia Han, Danielle Bitterman, Courtney L Jones, Nikki A Evensen, Margret Magid, Julia A Meyer, William L Carroll.   

Abstract

Primary neuroendocrine carcinomas (NEC) are rare tumors in children and young adults, resulting in a lack of standardized treatment approach. To refine the molecular taxonomy of these rare tumors, we performed whole exome sequencing in a pediatric patient with mediastinal NEC. We identified a somatic mutation in HRAS gene and LOH regions in NF2, MYO18B, and RUX3 genes. In addition, a germline heterozygous somatic variant in BRCA2 with LOH at that same position in the tumor tissue was also found. Our data provide valuable insight into the genomic landscape of this tumor, prompting further investigation of therapeutic targets.

Entities:  

Mesh:

Year:  2016        PMID: 26558807      PMCID: PMC4681625          DOI: 10.1097/MPH.0000000000000463

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  18 in total

1.  A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.

Authors:  C S Healey; A M Dunning; M D Teare; D Chase; L Parker; J Burn; J Chang-Claude; A Mannermaa; V Kataja; D G Huntsman; P D Pharoah; R N Luben; D F Easton; B A Ponder
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

2.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Authors:  M L Fjällskog; D P Granberg; S L Welin; C Eriksson; K E Oberg; E T Janson; B K Eriksson
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

Review 3.  Primary neuroendocrine carcinomas of the mediastinum: review of current criteria for histopathologic diagnosis and classification.

Authors:  Cesar A Moran
Journal:  Semin Diagn Pathol       Date:  2005-08       Impact factor: 3.464

4.  Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.

Authors:  Daphne Ang; Morgan Ballard; Carol Beadling; Andrea Warrick; Amy Schilling; Rebecca O'Gara; Marina Pukay; Tanaya L Neff; Robert B West; Christopher L Corless; Megan L Troxell
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-02

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 6.  Primary neuroendocrine tumors of the thymus.

Authors:  Rabih Chaer; Malek G Massad; Alexander Evans; Norman J Snow; Alexander S Geha
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

Review 7.  Uncommon primary mediastinal tumours.

Authors:  Paolo Macchiarini; Helmut Ostertag
Journal:  Lancet Oncol       Date:  2004-02       Impact factor: 41.316

8.  Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

Authors:  Nicola J Curtin; Lan-Zhen Wang; Anthie Yiakouvaki; Suzanne Kyle; Christine A Arris; Stacie Canan-Koch; Stephen E Webber; Barbara W Durkacz; Hilary A Calvert; Zdenek Hostomsky; David R Newell
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

Review 9.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 10.  MEK and the inhibitors: from bench to bedside.

Authors:  Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-12       Impact factor: 17.388

View more
  3 in total

1.  Expanding the clinical history associated with syndromic Klippel-Feil: A unique case of comorbidity with medulloblastoma.

Authors:  Kathleen M Schieffer; Elizabeth Varga; Katherine E Miller; Vibhuti Agarwal; Daniel C Koboldt; Patrick Brennan; Benjamin Kelly; Ashita Dave-Wala; Christopher R Pierson; Jonathan L Finlay; Mohamed S AbdelBaki; Peter White; Vincent Magrini; Richard K Wilson; Elaine R Mardis; Catherine E Cottrell
Journal:  Eur J Med Genet       Date:  2019-06-10       Impact factor: 2.708

Review 2.  Multifaceted Function of Myosin-18, an Unconventional Class of the Myosin Superfamily.

Authors:  Zhaohui Ouyang; Shuangshuang Zhao; Su Yao; Jing Wang; Yanqin Cui; Ke Wei; Yaming Jiu
Journal:  Front Cell Dev Biol       Date:  2021-02-09

3.  Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature.

Authors:  Natalie Herold; Barbara Wappenschmidt; Birgid Markiefka; Katharina Keupp; Sandra Kröber; Eric Hahnen; Rita Schmutzler; Kerstin Rhiem
Journal:  Oncol Lett       Date:  2018-01-22       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.